This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Agilent Technologies Thought Leader Award Supports Dr. Carolyn Mountford, University Of Newcastle, Australia

Stocks in this article: A

Agilent Technologies Inc. (NYSE: A) today announced that Dr. Carolyn Mountford has received an Agilent Thought Leader Award in recognition of her innovative work using nuclear magnetic resonance (NMR) spectroscopy technology in cancer research.

Dr. Mountford is a professor of radiology at The University of Newcastle Australia School of Health Sciences, and Harvard Medical School. She is the director of Newcastle’s Magnetic Resonance Centre for Clinical Research and director of the Center for Clinical Spectroscopy at the Brigham and Women’s Hospital in Boston.

The award will support Dr. Mountford and her team at the University of Newcastle in their pioneering research on novel in vivo NMR techniques that may help identify breast cancer in high-risk women. Preliminary data suggest that NMR may detect early changes in breast tissue that reflect rapid tumor growth. Moreover, NMR may be used to analyze primary breast tumors to determine if the cancer cells have spread to the lymph nodes, preventing unnecessary surgery.

“NMR spectroscopy is a highly accurate and precise tool for analyzing human tissue,” said Dr. Mountford. “This technology could help pathologists diagnose breast cancer more quickly and accurately, enable surgeons to make more informed decisions and, ultimately, improve the quality of cancer care for patients.”

“Agilent is committed to facilitating solutions for personalized medicine, and we are excited to support Dr. Carolyn Mountford and her team in their quest to develop NMR-based screening techniques,” said Regina Schuck, Ph.D., vice president and general manager of Agilent’s Research Products Division. “If successful, these NMR strategies may well revolutionize the field of cancer research.”

Dr. Mountford and her team are using Agilent’s 400-MR NMR Spectrometer, the 7510-AS Autosampler, and NMR probes and software at a new state-of-the-art NMR imaging center at Hunter Medical Research Institute. The new facility features the most advanced scanning technology in the Southern Hemisphere.

The Agilent Thought Leader Award promotes fundamental scientific advances by contributing financial support, products and expertise to the research of influential thought leaders in the life sciences and chemical analysis space. Information about previous award recipients is available at Agilent’s Thought Leader Program website .

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.

On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,773.08 +95.18 0.57%
S&P 500 1,956.81 +5.99 0.31%
NASDAQ 4,464.1720 +11.38 0.26%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs